High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection

Open Forum Infectious Diseases
Janet LoSteven K Grinspoon

Abstract

Individuals infected with human immunodeficiency virus (HIV) have decreased high-density lipoprotein (HDL)-cholesterol and increased cardiovascular disease (CVD). Reverse cholesterol transport from macrophages may be inhibited by HIV and contribute to increased CVD. Human studies have not investigated longitudinal effects of HIV and antiretroviral therapy (ART) on cholesterol efflux. Subjects with acute HIV infection were randomized to ART or not. Cholesterol efflux capacity was determined ex vivo after exposure of murine macrophages to apolipoprotein B-depleted patient sera obtained at baseline and after 12 weeks. After 12 weeks, HIV RNA decreased most in subjects randomized to ART. Available data on cholesterol demonstrated that efflux capacity from Abca1(+/+) macrophages was increased most by sera obtained from ART-treated subjects (20.5% ± 5.0% to 24.3 % ± 6.9%, baseline to 12 weeks, P = .007; ART group [n = 6] vs 18.0 % ± 3.9% to 19.1 % ± 2.9%, baseline to 12 weeks, P = .30; untreated group [n = 6] [P = .04 ART vs untreated group]). Change in HIV RNA was negatively associated with change in Abca1(+/+) macrophage cholesterol efflux (r = - 0.62, P = .03), and this finding remained significant (P = .03) after controlling for ...Continue Reading

References

Jul 2, 1998·The New England Journal of Medicine·J O Kahn, B D Walker
Jun 6, 2000·The Journal of Infectious Diseases·W KhovidhunkitC Grunfeld
Jul 19, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Judith S CurrierSally Hodder
Oct 10, 2003·Advances in Cardiology·Daniel VittecoqGilles Chironi
Oct 28, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Akira KawamuraKeijiro Saku
Dec 8, 2004·Journal of the American College of Cardiology·Piero O BonettiAmir Lerman
Nov 2, 2006·PLoS Biology·Zahedi MujawarDmitri Sviridov
Apr 26, 2007·The Journal of Clinical Endocrinology and Metabolism·Virginia A TriantSteven K Grinspoon
Dec 7, 2007·Atherosclerosis·Honor RoseDmitri Sviridov
Feb 18, 2009·Circulation·Fiona C McGillicuddyMuredach P Reilly
Jul 14, 2010·The Journal of Infectious Diseases·Bela F AsztalosKeith G Mansfield
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
May 20, 2011·The New England Journal of Medicine·Myron S CohenBarton F Haynes
Mar 6, 2013·JAMA Internal Medicine·Matthew S FreibergAmy C Justice
Sep 18, 2013·The Journal of Infectious Diseases·Kathleen V FitchSteven K Grinspoon
Sep 18, 2013·Annals of Internal Medicine·Mathias Lichterfeld, Eric S Rosenberg
Mar 20, 2014·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Huanhuan L CuiDmitri Sviridov
Apr 2, 2014·Annals of Internal Medicine·Wendy S PostLisa P Jacobson

❮ Previous
Next ❯

Citations

Feb 14, 2016·The Lancet. Diabetes & Endocrinology·Eric NouSteven K Grinspoon
Nov 26, 2015·Current Opinion in HIV and AIDS·Chris T LongeneckerJason V Baker
Jul 15, 2015·Current Opinion in Lipidology·Donna Lee M DinnesLeonard Kritharides
Apr 9, 2016·AIDS·Eric NouSteven K Grinspoon
Mar 28, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Theodoros KelesidisJudith S Currier
Sep 26, 2017·The Journal of Clinical Endocrinology and Metabolism·Mabel ToribioMichael L Fitzgerald
Oct 27, 2018·Journal of Cellular Biochemistry·Sara SamadiAmir Avan
Apr 18, 2019·Current HIV/AIDS Reports·Emily Bowman, Nicholas T Funderburg
Sep 21, 2018·Frontiers in Endocrinology·Marcelo N PedroMario J A Saad
Feb 11, 2021·International Journal of Molecular Sciences·Leonor Jacobo-AlbaveraTeresa Villarreal-Molina
Jul 27, 2021·Frontiers in Cell and Developmental Biology·Lucas A TavaresLuis L P daSilva

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
enzyme-linked immunosorbent assay
ELISA

Clinical Trials Mentioned

NCT00705926

Software Mentioned

SAS JMP

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.